Last reviewed · How we verify
CLDN6 CAR-T — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
CLDN6 CAR-T (CLDN6 CAR-T) — BioNTech Cell & Gene Therapies GmbH.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| CLDN6 CAR-T TARGET | CLDN6 CAR-T | BioNTech Cell & Gene Therapies GmbH | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- CLDN6 CAR-T CI watch — RSS
- CLDN6 CAR-T CI watch — Atom
- CLDN6 CAR-T CI watch — JSON
- CLDN6 CAR-T alone — RSS
Cite this brief
Drug Landscape (2026). CLDN6 CAR-T — Competitive Intelligence Brief. https://druglandscape.com/ci/cldn6-car-t. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing